{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:51:05Z","timestamp":1790297465472,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.biopha.2023.116036","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T18:19:47Z","timestamp":1703182787000},"page":"116036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Biomechanical response of ultrathin slices of hypertrophic cardiomyopathy tissue to myosin modulator mavacamten"],"prefix":"10.1016","volume":"170","author":[{"given":"Jorik H.","family":"Amesz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne J.J.","family":"Langmuur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier C.","family":"Manintveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arend F.L.","family":"Schinkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasja M.S.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick J.H.J.","family":"Taverne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.biopha.2023.116036_bib1","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.biopha.2023.116036_bib2","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","article-title":"Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy","volume":"121","author":"Marian","year":"2017","journal-title":"Circ. Res"},{"issue":"4","key":"10.1016\/j.biopha.2023.116036_bib3","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1161\/CIRCHEARTFAILURE.112.000122","article-title":"Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with beta-blockade or verapamil","volume":"6","author":"Sherrid","year":"2013","journal-title":"Circ. Heart Fail"},{"issue":"2014","key":"10.1016\/j.biopha.2023.116036_bib4","first-page":"2733","article-title":"ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy","volume":"35","author":"Uk","year":"2014","journal-title":"Eur. Heart J."},{"issue":"9","key":"10.1016\/j.biopha.2023.116036_bib5","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/ejhf.541","article-title":"Pharmacological treatment of hypertrophic cardiomyopathy: current practice and novel perspectives","volume":"18","author":"Ammirati","year":"2016","journal-title":"Eur. J. Heart Fail"},{"issue":"14","key":"10.1016\/j.biopha.2023.116036_bib6","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/eurheartj\/ehs150","article-title":"Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence","volume":"33","author":"Spoladore","year":"2012","journal-title":"Eur. Heart J."},{"issue":"40","key":"10.1016\/j.biopha.2023.116036_bib7","doi-asserted-by":"crossref","first-page":"16571","DOI":"10.1074\/jbc.M117.776815","article-title":"A small-molecule modulator of cardiac myosin acts on multiple stages of the myosin chemomechanical cycle","volume":"292","author":"Kawas","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"6273","key":"10.1016\/j.biopha.2023.116036_bib8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1126\/science.aad3456","article-title":"A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice","volume":"351","author":"Green","year":"2016","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.biopha.2023.116036_bib9","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann. Intern. Med."},{"issue":"10253","key":"10.1016\/j.biopha.2023.116036_bib10","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"E.-H.s. investigators, Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"issue":"10293","key":"10.1016\/j.biopha.2023.116036_bib11","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Spertus","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.biopha.2023.116036_bib12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.biopha.2023.116036_bib13","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1080\/00498254.2018.1495856","article-title":"In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin","volume":"49","author":"Grillo","year":"2019","journal-title":"Xenobiotica"},{"issue":"3","key":"10.1016\/j.biopha.2023.116036_bib14","doi-asserted-by":"crossref","first-page":"H1112","DOI":"10.1152\/ajpheart.00325.2020","article-title":"Mavacamten preserves length-dependent contractility and improves diastolic function in human engineered heart tissue","volume":"320","author":"Sewanan","year":"2021","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"3","key":"10.1016\/j.biopha.2023.116036_bib15","doi-asserted-by":"crossref","first-page":"H715","DOI":"10.1152\/ajpheart.00023.2020","article-title":"Mavacamten rescues increased myofilament calcium sensitivity and dysregulation of Ca(2+) flux caused by thin filament hypertrophic cardiomyopathy mutations","volume":"318","author":"Sparrow","year":"2020","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"8","key":"10.1016\/j.biopha.2023.116036_bib16","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1161\/CIRCRESAHA.118.314505","article-title":"SarcTrack","volume":"124","author":"Toepfer","year":"2019","journal-title":"Circ. Res."},{"issue":"476","key":"10.1016\/j.biopha.2023.116036_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat1199","article-title":"Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin","volume":"11","author":"Toepfer","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biopha.2023.116036_bib18","doi-asserted-by":"crossref","first-page":"1227184","DOI":"10.3389\/fbioe.2023.1227184","article-title":"Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment","volume":"11","author":"Wang","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"10","key":"10.1016\/j.biopha.2023.116036_bib19","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1161\/CIRCULATIONAHA.119.042339","article-title":"Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy","volume":"141","author":"Toepfer","year":"2020","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.biopha.2023.116036_bib20","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/CIRCULATIONAHA.121.056265","article-title":"Muscle LIM protein force-sensing mediates sarcomeric biomechanical signaling in human familial hypertrophic cardiomyopathy","volume":"145","author":"Riaz","year":"2022","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.biopha.2023.116036_bib21","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/eurheartj\/ehz779","article-title":"Living myocardial slices: a novel multicellular model for cardiac translational research","volume":"41","author":"Perbellini","year":"2020","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.biopha.2023.116036_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41467-018-08003-1","article-title":"Long-term functional and structural preservation of precision-cut human myocardium under continuous electromechanical stimulation in vitro","volume":"10","author":"Fischer","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2023.116036_bib23","article-title":"Omecamtiv mecarbil in precision-cut living heart failure slices: a story of a double-edged sword","volume":"5","author":"Amesz","year":"2023","journal-title":"J. Mol. Cell. Cardiol. Plus"},{"key":"10.1016\/j.biopha.2023.116036_bib24","article-title":"Acute biomechanical effects of empagliflozin on living isolated human heart failure myocardium","author":"Amesz","year":"2023","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"1","key":"10.1016\/j.biopha.2023.116036_bib25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/cvr\/cvr259","article-title":"Organotypic slice culture from human adult ventricular myocardium","volume":"93","author":"Brandenburger","year":"2011","journal-title":"Cardiovasc. Res."},{"issue":"3","key":"10.1016\/j.biopha.2023.116036_bib26","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1172\/JCI115061","article-title":"Diastolic dysfunction in hypertrophic cardiomyopathy. Effect on active force generation during systole","volume":"87","author":"Gwathmey","year":"1991","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.biopha.2023.116036_bib27","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/cvr\/cvr071","article-title":"Glucose metabolism and cardiac hypertrophy","volume":"90","author":"Kolwicz","year":"2011","journal-title":"Cardiovasc. Res."},{"issue":"2","key":"10.1016\/j.biopha.2023.116036_bib28","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0008-6363(97)00272-1","article-title":"Alterations in calcium handling in cardiac hypertrophy and heart failure","volume":"37","author":"Balke","year":"1998","journal-title":"Cardiovasc. Res."},{"issue":"6","key":"10.1016\/j.biopha.2023.116036_bib29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1085\/jgp.50.6.197","article-title":"ATPase activity of myosin correlated with speed of muscle shortening","volume":"50","author":"Barany","year":"1967","journal-title":"J. Gen. Physiol."},{"issue":"6023","key":"10.1016\/j.biopha.2023.116036_bib30","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1126\/science.1200113","article-title":"Cardiac myosin activation: a potential therapeutic approach for systolic heart failure","volume":"331","author":"Malik","year":"2011","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.biopha.2023.116036_bib31","doi-asserted-by":"crossref","first-page":"H373","DOI":"10.1152\/ajpheart.00534.2021","article-title":"Comprehensive analyses of the inotropic compound omecamtiv mecarbil in rat and human cardiac preparations","volume":"322","author":"Rhoden","year":"2022","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.biopha.2023.116036_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/ehf2.14300","article-title":"Omecamtiv mecarbil augments cardiomyocyte contractile activity both at resting and systolic Ca(2+) levels","author":"R\u00e1duly","year":"2023","journal-title":"ESC Heart Fail"},{"issue":"7","key":"10.1016\/j.biopha.2023.116036_bib33","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/ejhf.1659","article-title":"Association between systolic ejection time and outcomes in heart failure by ejection fraction","volume":"22","author":"Patel","year":"2020","journal-title":"Eur. J. Heart Fail"},{"issue":"25","key":"10.1016\/j.biopha.2023.116036_bib34","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","article-title":"Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Hegde","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.biopha.2023.116036_bib35","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/01.CIR.64.4.787","article-title":"Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy","volume":"64","author":"Bonow","year":"1981","journal-title":"Circulation"},{"issue":"32","key":"10.1016\/j.biopha.2023.116036_bib36","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/eurheartj\/eht070","article-title":"Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy","volume":"34","author":"Coats","year":"2013","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.biopha.2023.116036_bib37","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.112.134932","article-title":"Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy","volume":"127","author":"Coppini","year":"2013","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.biopha.2023.116036_bib38","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s003950050134","article-title":"Altered force-frequency relation in hypertrophic obstructive cardiomyopathy","volume":"94","author":"Schotten","year":"1999","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.biopha.2023.116036_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmpb.2023.107372","article-title":"Computational modeling of electromechanical coupling in human cardiomyocyte applied to study hypertrophic cardiomyopathy and its drug response","volume":"231","author":"Liu","year":"2023","journal-title":"Comput. Methods Prog. Biomed."},{"issue":"2","key":"10.1016\/j.biopha.2023.116036_bib40","doi-asserted-by":"crossref","first-page":"H881","DOI":"10.1152\/ajpheart.00345.2020","article-title":"Mavacamten decreases maximal force and Ca(2+) sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy","volume":"320","author":"Awinda","year":"2021","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"3","key":"10.1016\/j.biopha.2023.116036_bib41","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00210-022-02333-0","article-title":"Effects of omecamtiv mecarbil and mavacamten in isolated human atrium","volume":"396","author":"Abella","year":"2023","journal-title":"Naunyn Schmiede Arch. Pharm."},{"issue":"8","key":"10.1016\/j.biopha.2023.116036_bib42","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40265-022-01728-w","article-title":"Pharmacological management of hypertrophic cardiomyopathy: from bench to bedside","volume":"82","author":"Palandri","year":"2022","journal-title":"Drugs"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223018346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223018346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:49:37Z","timestamp":1773967777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223018346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":42,"alternative-id":["S0753332223018346"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.116036","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomechanical response of ultrathin slices of hypertrophic cardiomyopathy tissue to myosin modulator mavacamten","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.116036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116036"}}